XML 44 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Organization and Summary of Significant Accounting Policies (Tables)
6 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Schedule of Revenue by Type
The following table represents the Company’s revenue by type for the transition period ended December 31, 2020, and the fiscal years ended June 30, 2020, 2019, and 2018:
Transition Period Ended December 31,Years Ended June 30,
(In millions)2020202020192018
Molecular diagnostic revenues:
Hereditary Cancer Testing$159.3 $347.4 $479.7 $471.4 
GeneSight29.8 74.1 112.6 124.9 
Prenatal37.6 76.7 104.9 — 
Vectra18.0 39.1 48.3 55.2 
myChoice CDx13.2 13.1 7.1 5.1 
Prolaris14.8 24.7 25.5 21.5 
EndoPredict5.9 10.5 10.4 8.8 
Other1.0 1.3 0.9 3.5 
Total molecular diagnostic revenue279.6 586.9 789.4 690.4 
Pharmaceutical and clinical service revenue20.2 51.7 61.7 53.3 
Total revenue$299.8 $638.6 $851.1 $743.7 
Reconciliation of Deferred Revenue Balances A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
Transition Period Ended December 31, Years Ended June 30,
(in millions)202020202019
Deferred revenue - beginning balance$32.8 $2.2 $2.6 
Revenue recognized(6.1)(7.2)(7.9)
Prepayments6.0 37.8 7.5 
Deferred revenue - ending balance$32.7 $32.8 $2.2 
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations
The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:
Transition Period Ended December 31,Years Ended June 30,
(in millions)2020202020192018
Denominator:
Weighted-average shares outstanding used to compute
basic EPS
75.0 74.3 73.5 69.4 
Effect of dilutive stock options— — 2.5 2.6 
Weighted-average shares outstanding and dilutive
securities used to compute diluted EPS
75.0 74.3 76.0 72.0 
Schedule of Potential Dilutive Common Shares These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
Transition Period Ended December 31,Years Ending June 30,
(in millions)2020202020192018
Anti-dilutive options and RSUs excluded from EPS computation
6.6 5.5 0.8 — 
Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss
The following table shows the cumulative translation adjustments included in Accumulated other comprehensive income (loss) (in millions):
Ending balance June 30, 2020$(6.5)
Period translation adjustments2.4 
Other1.0 
Ending balance December 31, 2020$(3.1)